ArticleThe Journal of pharmacy and pharmacology2017
Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies.
Article in The Journal of pharmacy and pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Viburnum opulus protects against acetaminophen-induced splenic injury through coordinated antioxidant and anti-inflammatory responses.Journal of molecular histology · 2026Article
- Hepatoprotective Effects of Flavonoids Against Acetaminophen Toxicity.Molecules (Basel, Switzerland) · 2026Review
- The quercetin-serotonin transporter (SERT) connection: a new hope for depression therapy?Psychopharmacology · 2026Review
- Hepatoprotective Effects of Flavonoids against Benzo[a]Pyrene-Induced Oxidative Liver Damage along Its Metabolic Pathways.Antioxidants (Basel, Switzerland) · 2024Review
- Effects of three flavonoids on the metabolism of lenvatinib.Frontiers in pharmacology · 2024Article
- Luteolin and Vernodalol as Bioactive Compounds of Leaf and RootPharmaceutics · 2023Article
- Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs.Frontiers in pharmacology · 2023Article
- Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC-MS/MS assay.Pharmaceutical biology · 2022Article
- Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles.Pharmaceutical biology · 2022Article
- Studies on Chemical Characterization of Ginkgo Amillaria Oral Solution and Its Drug-Drug Interaction With Piceatannol 3'-Frontiers in pharmacology · 2022Article
- Hepatoprotective effect of kaempferol glycosides isolated fromResearch in pharmaceutical sciences · 2021Article
- The Impact of Diet and Exercise on Drug Responses.International journal of molecular sciences · 2021Review
- Human Lanosterol 14-Alpha Demethylase (CYP51A1) Is a Putative Target for Natural Flavonoid Luteolin 7,3'-Disulfate.Molecules (Basel, Switzerland) · 2021Article
- Potential Herb-Drug Interactions in the Management of Age-Related Cognitive Dysfunction.Pharmaceutics · 2021Review
- Protective Effect ofTheScientificWorldJournal · 2021Article
- Article
- COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.BioFactors (Oxford, England) · 2020Article
- Strong and Selective Inhibitory Effects of the Biflavonoid Selamariscina A against CYP2C8 and CYP2C9 Enzyme Activities in Human Liver Microsomes.Pharmaceutics · 2020Article
- Hepatoprotective effect of essential oils ofBioscience reports · 2019Article
- The Essential Oils and Eucalyptol FromFrontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesExcessive exposure to acetaminophen (APAP, paracetamol) can cause liver injury through formation of a reactive metabolite that depletes hepatic glutathione and causes hepatocellular oxidative stress and damage. Generation of this metabolite is mediated by Cytochrome-P450 (CYP) isoforms, mainly CYP2E1. A number of naturally occurring flavonoids can mitigate APAP-induced hepatotoxicity in experimental animal models. Our objective was to determine the mechanism of these protective effects and to evaluate possible human applicability.
methodsTwo flavonoids, luteolin and quercetin, were evaluated as potential inhibitors of eight human CYP isoforms, of six UDP-glucuronosyltransferase (UGT) isoforms and of APAP glucuronidation and sulfation. The experimental model was based on in-vitro metabolism by human liver microsomes, using isoform-specific substrates. KEY
findingsLuteolin and quercetin inhibited human CYP isoforms to varying degrees, with greatest potency towards CYP1A2 and CYP2C8. However, 50% inhibitory concentrations (IC
conclusionsInhibition of human CYP activity by luteolin and quercetin occurred with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.